Chinese expert consensus on antiangiogenic drugs for advanced non-small cell lung cancer (2020 Edition).
10.3760/cma.j.cn112152-20200918-00836
- VernacularTitle:晚期非小细胞肺癌抗血管生成药物治疗中国专家共识(2020版)
- Collective Name:Expert Committee on Vessel Targeted Therapy of Chinese Society of Clinical Oncology;Expert Committee on Non-small Cell Lung Cancer of Chinese Society of Clinical Oncology;Expert Group on Antiangiogenic Drugs for Non-small Cell Lung Cancer of Chinese Society of Clinical Oncology
- Publication Type:Journal Article
- Keywords:
Angiogenesis inhibitor;
Expert consensus;
Neoplasms, non-small cell lung
- MeSH:
Angiogenesis Inhibitors/therapeutic use*;
Carcinoma, Non-Small-Cell Lung/pathology*;
China;
Consensus;
Humans;
Lung Neoplasms/pathology*;
Neoplasm Staging
- From:
Chinese Journal of Oncology
2020;42(12):1063-1077
- CountryChina
- Language:Chinese
-
Abstract:
Non-small cell lung cancer (NSCLC) is the most common histological type of lung cancer, accounting for more than 80% of primary lung cancer. Platinum-based chemotherapy is the traditional standard for the treatment of advanced NSCLC, but the 5-years survival rate is still very low, less than 5%. Angiogenesis plays an important role in the growth, proliferation and metastasis of solid tumors. Angiogenesis inhibitors affect the tumor microenvironment, degenerate existing tumor blood vessels and inhibit tumor angiogenesis. Angiogenesis inhibitors are now one of the indispensable treatments for patients with advanced NSCLC through continuous development of new angiogenesis inhibitor and improvement of drug accessibility. This consensus is based on the "Expert consensus on anti-angiogenic drug therapy for advanced non-small cell lung cancer in China (2019 Edition)" , combines with clinical research evidence published in the past years and clinical experience. The consensus-writing group compiles a consensus of guiding clinical departments related to lung cancer treatment to use anti-angiogenic drugs in a standardized manner, and further improves the level of standardized diagnosis and treatment of lung cancer.
